Hemostemix Inc. HMTXF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.41% | -10.81% | 51.02% | 141.43% | 60.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.51% | 93.43% | 176.22% | 187.62% | 71.21% |
| Operating Income | -94.51% | -93.43% | -176.22% | -187.62% | -71.21% |
| Income Before Tax | -47.21% | -22.32% | -74.14% | -60.75% | -55.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.21% | -22.32% | -74.14% | -60.75% | -55.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.21% | -22.32% | -74.14% | -60.75% | -55.96% |
| EBIT | -94.51% | -93.43% | -176.22% | -187.62% | -71.21% |
| EBITDA | -94.51% | -93.42% | -176.21% | -187.64% | -71.22% |
| EPS Basic | 20.00% | 35.39% | -14.29% | -29.81% | -32.91% |
| Normalized Basic EPS | -6.34% | -1.32% | -58.47% | -35.71% | -17.36% |
| EPS Diluted | 20.00% | 35.39% | -14.29% | -29.81% | -32.91% |
| Normalized Diluted EPS | -6.34% | -1.32% | -58.47% | -35.71% | -17.36% |
| Average Basic Shares Outstanding | 63.72% | 73.68% | 59.32% | 40.76% | 25.19% |
| Average Diluted Shares Outstanding | 63.72% | 73.68% | 59.32% | 40.76% | 25.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |